Jade Biosciences, Inc.
Jade Biosciences, Inc. (JBIO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
jbio · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Jade Biosciences, Inc. (JBIO) measures how much investors pay for each dollar of the company's trailing earnings. JBIO's current PE ratio of N/A is calculated by dividing its stock price of $15.17 by its TTM earnings per share of -$2.24.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2020 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Jade Biosciences, Inc.You JBIO | $495M | N/A | — | -$2.24 |
 AC Immune S.A. ACIU | $222M | N/A | — | -$0.70 |
 Aldeyra Therapeutics, Inc. ALDX | $105M | N/A | — | -$0.56 |
 Contineum Therapeutics, Inc. Class A Common Stock CTNM | $431M | N/A | — | -$2.17 |
 Genelux Corporation GNLX | $110M | N/A | — | -$0.86 |
 Kyverna Therapeutics, Inc. KYTX | $338M | N/A | — | -$3.64 |
 Lyell Immunopharma, Inc. LYEL | $287M | N/A | — | -$16.06 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-4.06 | — | |
2024-12-31 FY2024 | — | $-85.26 | — | |
2023-12-31 FY2023 | — | $-100.38 | — | |
2022-12-31 FY2022 | — | $-73.67 | — | |
2021-12-31 FY2021 | — | $-32.92 | — | |
2020-12-31 FY2020 | — | $-13.78 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Jade Biosciences, Inc. (JBIO) measures how much investors pay for each dollar of the company's trailing earnings. JBIO's current PE ratio of N/A is calculated by dividing its stock price of $15.17 by its TTM earnings per share of -$2.24.
Frequently asked questions
JBIO pe ratio · 6 questionsJBIO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $15.17 and TTM EPS of -$2.24. Data sourced from Financial Modeling Prep via JBIO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Jade Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09